# Lyell Immunopharma (LYEL) — News

LYEL · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/lyel/news

## Recent headlines

- [Lyell's Lyl273 phase 1/2 data, FDA meeting now due in 2027](https://www.ainvest.com/news/lyell-lyl273-phase-1-2-data-fda-meeting-due-2027-2609) — AInvest Wire, Sep 10, 2026
- [Lyell completes Lyl273 manufacturing transfer to Lyfe](https://www.ainvest.com/news/lyell-completes-lyl273-manufacturing-transfer-lyfe-2609) — AInvest Wire, Sep 10, 2026
- [Lyell Immunopharma: Additional clinical data and end-of-phase 1 FDA meeting expected in 2027](https://www.ainvest.com/news/lyell-immunopharma-additional-clinical-data-phase-1-fda-meeting-expected-2027-2609) — AInvest Wire, Sep 10, 2026
- [Lyell Immunopharma Q2 operating income USD -47.337 million](https://www.ainvest.com/news/lyell-immunopharma-q2-operating-income-usd-47-337-million-2608) — AInvest Wire, Aug 6, 2026
- [Lyell Immunopharma Q2 operating expenses USD 47.341 million](https://www.ainvest.com/news/lyell-immunopharma-q2-operating-expenses-usd-47-341-million-2608) — AInvest Wire, Aug 6, 2026

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).